Senseonics Holdings, Inc. (NYSE:SENS) Receives Average Rating of “Buy” from Brokerages

Shares of Senseonics Holdings, Inc. (NYSE:SENS) have been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $22.70.

A number of research firms have recently issued reports on SENS. Stifel Nicolaus assumed coverage on Senseonics in a research note on Tuesday, October 21st. They issued a “hold” rating and a $9.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Senseonics in a report on Thursday, January 8th. Barclays restated an “overweight” rating and set a $31.00 price target (up from $1.50) on shares of Senseonics in a research note on Wednesday, November 5th. Finally, HC Wainwright increased their price objective on shares of Senseonics to $18.50 and gave the stock a “buy” rating in a research note on Thursday, November 6th.

Senseonics Stock Up 0.5%

Shares of Senseonics stock opened at $7.55 on Wednesday. Senseonics has a twelve month low of $5.25 and a twelve month high of $25.60. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The company’s 50 day moving average is $6.88 and its 200 day moving average is $7.66. The company has a market cap of $308.49 million, a price-to-earnings ratio of -58.08 and a beta of 0.99.

Institutional Investors Weigh In On Senseonics

A number of hedge funds have recently modified their holdings of SENS. First Light Asset Management LLC raised its stake in Senseonics by 666.7% during the 2nd quarter. First Light Asset Management LLC now owns 35,708,124 shares of the company’s stock valued at $17,011,000 after purchasing an additional 31,050,619 shares during the period. Vanguard Group Inc. grew its stake in Senseonics by 2.2% during the third quarter. Vanguard Group Inc. now owns 34,219,484 shares of the company’s stock valued at $14,920,000 after acquiring an additional 749,453 shares in the last quarter. Geode Capital Management LLC increased its holdings in Senseonics by 26.6% in the 2nd quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company’s stock valued at $4,147,000 after acquiring an additional 1,828,302 shares during the last quarter. Hood River Capital Management LLC bought a new stake in Senseonics in the 2nd quarter valued at $3,775,000. Finally, Masters Capital Management LLC lifted its stake in Senseonics by 11.1% in the 3rd quarter. Masters Capital Management LLC now owns 5,000,000 shares of the company’s stock worth $2,179,000 after purchasing an additional 500,000 shares in the last quarter. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.